Petlife Pharmaceuticals, Inc.
PTLF · OTC
8/31/2017 | 8/31/2016 | 8/31/2015 | 8/31/2014 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.00 | 0.02 |
| FCF Yield | -74.16% | -44.38% | -26.33% | -10.24% |
| EV / EBITDA | -0.05 | -0.13 | -0.04 | -1.72 |
| Quality | ||||
| ROIC | 3,410.55% | 119.64% | 529.19% | -8,673.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.01 | 0.04 | 0.01 | 0.18 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -110.04% | -570.84% | 91.52% | -94.80% |
| Safety | ||||
| Net Debt / EBITDA | -0.03 | -0.04 | 0.00 | 0.00 |
| Interest Coverage | -59.04 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -389.30 | 0.00 |